Corcept Therapeutics
NEWS
Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. On Tuesday, QurAlis presented interim Phase 2 data showing the potential of a similar drug to more broadly treat the neurodegenerative disease.
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant, which it rejected last September, triggering a very public dispute with the company.
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer’s, Acer’s vEDS program hits Phase III and BridgeBio’s primary hyperoxaluria type 1 program progresses.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
It’s a promising day for advanced ovarian cancer research as two biopharma companies achieved positive results. Here’s what you need to know about research.
After yesterday’s big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be the key word to describe the stock market.
A look at two life science companies that are expected to grow more than 67 percent over the next five years.
JOBS
IN THE PRESS